Endocrine therapy of breast cancer

Annals of Oncology

Volumn 13, Issue SUPPL. 4, 2002, Pages 61-68

  Goldhirsch, A ^a,b   Gelber R d, Colleoni M ^a,c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b Ospedale Civico Lugano   (Switzerland)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; 7 HYDROXY 3 PHENYL 4 [4 (2 PIPERIDINOETHOXY)BENZYL] 2H CHROMEN 2 ONE; ACOLBIFENE; AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; ANTIANDROGEN; ANTIESTROGEN; ANTIGESTAGEN; AROMATASE INHIBITOR; ARZOXIFENE; BAZEDOXIFENE; DROLOXIFEN; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FORMESTANE; FULVESTRANT; GESTAGEN; GONADORELIN DERIVATIVE; GOSERELIN; IDOXIFENE; LETROZOLE; MEDROXYPROGESTERONE ACETATE; RALOXIFENE; SCH 57068; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADRENALECTOMY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG TARGETING; DRUG WITHDRAWAL; FEMALE; HISTORY; HUMAN; HYPOPHYSECTOMY; OVARIECTOMY; OVARY FUNCTION; PATIENT SELECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 0036436071     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf640     Document Type: Article

References (80)

1. Goldhirsch A, Gelber RD. Endocrine therapies of breast cancer. Semin Oncol 1996; 23: 494-505.
2. Sutherland DJ, Mobbs BG. Hormones and cancer. In Tannock IF and Hill RP (eds): The Basic Science of Oncology, 2nd edition. New York, NY: McGraw-Hill 1992; 207-231.
3. Decensi A, Torrisi R, Fontana V et al. Correlation between plasma transforming growth factor-β1 and second primary breast cancer in a chemoprevention trial. Eur J Cancer 1998; 34: 999-1003.
4. Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001; 6: 469-477.
5. Gustafsson J-Å. Estrogen receptor β: a new dimension in estrogen mechanism of action. J Endocrinol 2000; 163: 379-383.
6. Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 2000; 15: 817-825.
7. Santen R, Jeng MH, Wang JP et al. Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J Steroid Biochem Mol Biol 2001; 79: 115-125.
8. Reddy KB, Yee D, Hilsenbeck SG et al. Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor α expression. Cell Growth Differer 1994; 5: 1275-1282.
9. Harbeck N, Alt U, Berger U et al. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 2001; 7: 2757-2764.
10. Reddel RR, Sutherland RL. Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro. Cancer Res 1987; 47: 5323-5329.
11. Wolf DM, Gottardis MM, Jordan VC. Tamoxifen-resistant growth. In Jordan VC (ed.): Long-term Tamoxifen Treatment for Breast Cancer. Madison, WI: University of Wisconsin Press 1994; 200-217.
12. Love RR. Multisystem biological and symptomatic toxicity of tamoxifen in postmenopausal women. In Jordan VC (ed.): Long-term Tamoxifen Treatment for Breast Cancer. Madison, WI: University of Wisconsin Press 1994; 57-81.
13. Musgrove EA, Sutherland RL. Steroids, growth factors, and cell cycle controls in breast cancer. In Lippman M and Dickson R (eds): Regulatory Mechanisms in Breast Cancer. Boston, MA: Kluwer 1991; 305-331.
14. Pollak M, Costantino J, Polychronakos C et al. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 1990; 82: 1693-1697.
15. Knabbe C, Lippman ME, Wakefield L et al. Evidence that TGF-β is a hormonally regulated negative growth factor in human breast cancer. Cell 1987; 48: 417-428.
16. Colletta AA, Wakefield LM, Howell FV et al. Anti-oestrogen induces the secretion of active transforming growth factor β from human fetal fibroblasts. Br J Cancer 1990; 62: 405-409.
17. Levenson AS, Jordan VC. Selective oestrogen receptor modulation: molecular pharmacology for the millennium. Eur J Cancer 1999; 14: 1974-1985.
18. Wakeling AE. A new approach to breast cancer therapy: total estrogen ablation with pure antiestrogens. In Jordan VC (ed.): Long-term Tamoxifen Treatment for Breast Cancer. Madison, WI: University of Wisconsin Press 1994; 219-234.
19. Labrie F, Labrie C, Be'langer A et al. EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. J Steroid Biochem Mol Biol 2001; 79: 213-225.
20. Allegra JC, Kiefer SM. Mechanisms of action of progestational agents. Semin Oncol 1985; 12 (Suppl. 2): 3-5.
21. Birrell SN, Roder DM, Horsfall DJ et al. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. J Clin Oncol 1995; 13: 1572-1577.
22. Masamura S, Adlercreutz H, Harvey H et al. Aromatase inhibitors development for treatment in breast cancer. Breast Cancer Res Treat 1995; 33: 19-26.
23. Brodie A. Aromatase inhibitors in breast cancer. Trends Endocrinol Metabol 2002; 13: 61-65.
24. Dowsett M. Aromatase inhibition: basic concepts, and the pharmacodynamics of formestane. Ann Oncol 1994; 5 (Suppl. 7); 3-5.
25. Bossche HV, Moereels H, Koymans LMH. Aromatase inhibitors: mechanisms for non-steroidal inhibitors. Breast Cancer Res Treat 1994; 30: 43-55.
26. Coy DH, Schally AV. Gonadotrophin releasing hormone analogues. Ann Clin Res 1978; 10: 139-144.
27. Nicholson RI, Walker KJ, Turkes A et al. Therapeutic significance and the mechanism of action of the LH-RH agonist ICI 118630 in breast and prostate cancer. J Steroid Biochem 1984; 20: 129-135.
28. Baulieu EE. The steroid hormone antagonist RU486: mechanisms of the cellular level and clinical applications. Endocrinol Metab Clin North Am 1991; 20: 873-891.
29. Schneider MR, Michna H, Nishino Y et al. Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models. J Steroid Biochem Mol Biol 1990; 37: 783-787.
30. Klijn JG, Setyono-Han B, Foekens JA. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 2000; 65: 825-830.
31. Secreto G, Recchione C, Zambetti M et al. Hormonal changes induced by the pure antiandrogen flutamide in postmenopausal women with advanced breast cancer. Eur J Cancer Clin Oncol 1988; 24: 867-872.
32. Di Monaco M, Brignardello E, Leonardi L et al. Inhibitory effect of hydroxyflutamide plus tamoxifen on oestradiol-induced growth of MCF-7 breast cancer cells. J Cancer Res Clin Oncol 1995; 121: 710-714.
33. Wittliff JL, Pasic R, Bland KI. Steroid and peptide hormone receptors identified in breast tissue. In Bland KI, Copeland EM III (eds): The Breast: Comprehensive Management of Benign and Malignant Diseases. Philadelphia, PA: W.B. Saunders 1991; 900-936.
34. Harvey JM, Clark GM, Osborne CK et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481.
35. Horwitz KB. Mechanisms of hormone resistance in breast cancer. Breast Cancer Res Treat 1993; 26: 119-130.
36. Wolf DM, Langan-Fahey SM, Parker CP et al. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth using non-isomerizable analogs of tamoxifen and metabolites. J Natl Cancer Inst 1993; 85: 806-812.
37. Klijn JG, Berns EM, Bontenbal M, Foekens J. Cell biological factors associated with response of breast cancer to systemic treatment. Cancer Treat Rev 1993; 19 (Suppl. B): 45-63.
38. Dowsett M, Harper-Wynne C, Boeddinghaus I et al. HER2 amplification impedes the antiproliferative effects of hormonal therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001; 61: 8452-8458.
39. Dowsett M. Overexpression of HER2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 2001; 8: 191-195.
40. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or Erb-B2-positive, estrogen receptor positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808-3816.
41. Muss H, Berry D, Thor A et al. Lack of interaction of tamoxifen (T) use and erbB-2/HER-2/Neu (H) expression in CALGB 8541: a randomized adjuvant trial of three different doses of cyclophosphamide, doxorubicin and fluorouracil (CAF) in node-positive primary breast cancer (BC). J Clin Oncol 1999; 18: (Abstr 256).
42. Gill PG, Gebski V, Snyder R et al. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on the treatment response and survival in patients with metastatic breast cancer. Ann Oncol 1993; 9: 741-744.
43. Goldhirsch A, Gelber RD. Treatment of overt metastatic breast cancer. In Veronesi U (ed): Bailliere's Clinical Oncology. International Practice and Research. Breast Cancer 1988.
44. Zigrossi P, Brustia M, Bobbio F, Campanini M. Flare and tumor lysis syndrome with atypical features after letrozole therapy in advanced breast cancer. A case report. Ann Ital Med Int 2001; 16: 112-117.
45. Klijn JC, Beex LV, Mauriac L et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized trial. J Natl Cancer Inst 2000; 92: 903-911.
46. Stein RC, Dowsett M, Hedley A et al. The clinical and endocrine effects of 4-hydroxyandrostendione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 1990; 62: 679-683.
47. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18: 3758-3767.
48. Vergote I, Bonneterre J, Thürlimann B et al. Randomized study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. Eur J Cancer 2000; 36 (Suppl. 4): S84-S85.
49. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606.
50. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996; 348: 1189-1196.
51. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
52. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Clin Oncol 2001; 19: 3817-3827.
53. Baum M on behalf of the ATAC Trialists' Group. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in post-menopausal women. Breast Cancer Research Treatment. Special Issue: 24th Ann San Antonio Breast Cancer Symp 2001; 69: 210 (Abstr 8).
54. Boccardo F, Rubagotti A, Amoroso D et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J Clin Oncol 2001; 19: 4209-4215.
55. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international consensus panel on the treatment of primary breast cancer (letter). J Clin Oncol 2002; 20: 879-880.
56. Anderson ED, Forrest AP, Levack PA et al. Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer. Br J Cancer 1989; 60: 223-226.
57. Akhtar SS, Allan SG, Rodger A et al. A 10-year experience of tamoxifen as primary treatment of breast cancer in 100 elderly and frail patients. Eur J Surg Oncol 1991; 17: 30-35.
58. Soubeyran I, Quenel N, Mauriac L et al. Variation of hormonal receptor, pS2, c-erbB-2 and GSTπ contents in breast carcinomas under tamoxifen: a study of 74 cases. Br J Cancer 1996; 73: 735-743.
59. Willsher PC, Robertson JFR, Jackson L et al. Investigation of primary tamoxifen therapy for elderly patients with operable breast cancer. Breast 1997; 6: 150-154.
60. Gazet JC, Ford HT, Gray R et al. Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. Ann Oncol 2001; 12: 685-691.
61. Osborne CK. Effects of estrogens and antiestrogens on cell proliferation. Implications for treatment of breast cancer. In Osborne CK (ed): Endocrine Treatment in Breast and Prostate Cancer. Boston, MA: Kluwer 1988; 111-129.
62. Greensberg DA, Carpenter CL, Messing RO. Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC12 neurosecretory cell line. Cancer Res 1987; 47: 70-76.
63. Berman E, Adams M, Duigou-Ostendorf R et al. Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood 1991; 77: 818-822.
64. Sledge GW, Hu P, Falksin G et al. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer. An Eastern Cooperative Oncology Group study. J Clin Oncol 2000; 18: 262-266.
65. Cavalli F, Alberto P, Jungi WF et al. Simultaneous hormone- and chemotherapy, compared with hormone therapy followed by chemotherapy in the treatment of metastasizing mammary carcinoma: preliminary results of a current study. Recent Results Cancer Res 1980; 71: 151-154.
66. International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 1997; 15: 1385-1394.
67. Fisher B, Redmond C, Brown A et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer. Five-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 1986; 4: 459-471
68. Fisher B, Anderson S, Tan-Chiu E et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001; 19: 931-942
69. Meakin JW, Allt WE, Beale FA et al. Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Breast Cancer Res Treat 1983; 3 (Suppl.): S45-S48.
70. Celio L, Martinetti A, Ferrari L et al. Premenopausal breast cancer patients treated with gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res 1999; 19: 2261-2268.
71. Rose C, Kamby C, Mouridsen HT et al. Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen plus aminoglutethimide and hydrocortisone and tamoxifen plus fluoxymestrone in women above 65 years of age. Breast Cancer Res Treat 2000; 61: 103-110.
72. Mouridsen HT, Ellemann K, Mattson W et al. Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women. Cancer Treat Rep 1979; 63: 171-175.
73. Veronesi U, Maisonneuve P, Costa A et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998; 352: 93-97.
74. Russell CA, Green SJ, O'Sullivan J et al. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. J Clin Oncol 1997; 15: 2494-2501.
75. Hallowell H. You don't want to lose your ovaries because you think "I might become a man." Women's perceptions of prophylactic surgery as a cancer risk management option. Psychooncology 1998; 7: 263-275.
76. Berglund G, Nystedt M, Bolund C et al. Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized trial. J Clin Oncol 2001; 19: 2788-2796.
77. Cohen I, Figer A, Tepper T et al. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients. Gynecol Oncol 1999; 72: 202-207.
78. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2000; 64: 165-176.
79. Weitz IC, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer 1997; 79: 2024-2027.
80. Goss PE. Risks versus benefits in the clinical application of aromatase inhibitors. Endocr Rel Cancer 1999; 6: 325-332.